Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05800665 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

A Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer, sponsored by Genentech.

Recruiting
Registry status
Phase 1
Development phase
210
Enrollment target
20
Study locations

NCT05800665 is a Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer that is actively recruiting participants, run by Genentech. The registered enrollment target is 210 participants, above the 181-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05800665, a Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer, is actively recruiting participants, sponsored by Genentech.

RECRUITING
Registry status
Phase 1
Development phase
210 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.

Conditions Studied

Metastatic Prostate Cancer Advanced Prostate Cancer

Interventions

  • DRUG RO7656594

Study Locations (20)

Other

  • Centre Léon Bérard - Lyon
  • Institut Paoli Calmettes - Marseille
  • Seoul National University Hospital - Seoul
  • Severance Hospital Yonsei University Health System - PPDS - Seoul
  • Asan Medical Center - PPDS - Seoul
  • Samsung Medical Center - PPDS - Seoul
  • Hospital Universitario Vall d'Hebron - PPDS - Barcelona
  • Clinica Universidad de Navarra-Madrid - Madrid

New South Wales

  • St Vincent's Hospital Sydney - Darlinghurst
  • Macquarie University Hospital - New South Wales

Victoria

  • Monash Health Monash Medical Centre - Clayton
  • Austin Hospital - Heidelberg

Arizona

  • HonorHealth - Scottsdale

Connecticut

  • Yale Cancer Center - New Haven

Florida

  • Sarah Cannon Research Institute @ Florida Cancer - Orlando

Illinois

  • University of Illinois Hospital & Health Sciences System - Chicago

Texas

  • SCRI Oncology Partners - Nashville

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2023-05-02
Est. Completion 2027-06-30
Phase Phase 1

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05800665

The ClinicalTrials.gov registry entry for NCT05800665 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 181-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (16% higher). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which RO7656594 is the first listed.

NCT05800665 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, New South Wales, Victoria.

Frequently Asked Questions

What is clinical trial NCT05800665 about?

NCT05800665 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.

What is the current status of trial NCT05800665?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2023-05-02. Estimated completion is 2027-06-30.

What conditions does trial NCT05800665 study?

This clinical trial studies the following conditions: Metastatic Prostate Cancer, Advanced Prostate Cancer.

What interventions are being tested in trial NCT05800665?

The interventions under investigation include: RO7656594 (DRUG).

Who is sponsoring clinical trial NCT05800665?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05800665 being conducted?

This trial has 20 study locations across Arizona, Connecticut, Florida, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Prostate Cancer

All registered trials for this condition

Advanced Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.